Agilent Technologies, Inc. to Post Q1 2018 Earnings of $0.57 Per Share, Jefferies Group Forecasts (A)
Agilent Technologies, Inc. (NYSE:A) – Research analysts at Jefferies Group upped their Q1 2018 earnings estimates for Agilent Technologies in a note issued to investors on Tuesday. Jefferies Group analyst B. Couillard now forecasts that the medical research company will post earnings of $0.57 per share for the quarter, up from their prior estimate of $0.56. Jefferies Group currently has a “Buy” rating and a $66.00 price objective on the stock. Jefferies Group also issued estimates for Agilent Technologies’ Q2 2018 earnings at $0.64 EPS.
Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Agilent Technologies had a return on equity of 16.96% and a net margin of 15.30%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.59 EPS.
Several other research analysts have also issued reports on the company. Robert W. Baird reaffirmed a “buy” rating and set a $70.00 target price on shares of Agilent Technologies in a research report on Friday, October 20th. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 target price on the stock in a research report on Tuesday, October 10th. Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a research report on Tuesday, November 14th. Deutsche Bank AG set a $68.00 target price on Agilent Technologies and gave the company a “buy” rating in a research report on Wednesday, August 16th. Finally, BidaskClub lowered Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $68.34.
Agilent Technologies (NYSE:A) opened at $69.36 on Thursday. Agilent Technologies has a 1 year low of $42.92 and a 1 year high of $70.81. The stock has a market capitalization of $22,106.37, a PE ratio of 28.98, a P/E/G ratio of 2.07 and a beta of 1.27. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.76 and a current ratio of 3.30.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 2nd will be paid a $0.149 dividend. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date is Friday, December 29th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.86%. Agilent Technologies’s dividend payout ratio is presently 25.24%.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 22,481 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $70.00, for a total transaction of $1,573,670.00. Following the transaction, the chief executive officer now owns 327,882 shares in the company, valued at $22,951,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Boon Hwee Koh sold 4,500 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total value of $286,335.00. The disclosure for this sale can be found here. Insiders sold 107,709 shares of company stock worth $7,195,576 in the last 90 days.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. lifted its position in shares of Agilent Technologies by 0.3% in the second quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 10 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its position in shares of Agilent Technologies by 0.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock valued at $276,000 after acquiring an additional 35 shares in the last quarter. Veritable L.P. lifted its position in shares of Agilent Technologies by 0.4% in the second quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock valued at $646,000 after acquiring an additional 40 shares in the last quarter. Balentine LLC lifted its position in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after acquiring an additional 50 shares in the last quarter. Finally, Kingfisher Capital LLC lifted its position in shares of Agilent Technologies by 0.3% in the second quarter. Kingfisher Capital LLC now owns 22,643 shares of the medical research company’s stock valued at $1,343,000 after acquiring an additional 58 shares in the last quarter.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.